{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:40:23Z","timestamp":1787017223857,"version":"build-2736575974"},"reference-count":31,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"published-print":{"date-parts":[[2014,11,1]]},"DOI":"10.1136\/jnnp-2013-307282","type":"journal-article","created":{"date-parts":[[2014,3,22]],"date-time":"2014-03-22T00:03:32Z","timestamp":1395446612000},"page":"1198-1208","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":140,"title":["Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial"],"prefix":"10.1136","volume":"85","author":[{"given":"T.","family":"Olsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Boster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Berkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sidorenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.-W.","family":"Radue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Melanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2014,3,21]]},"reference":[{"key":"key-10.1136\/jnnp-2013-307282-1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"372","author":"Compston","year":"2008","journal-title":"Lancet"},{"key":"key-10.1136\/jnnp-2013-307282-2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s100720170011","article-title":"The prevalence of multiple sclerosis in the world: an update","volume":"22","author":"Rosati","year":"2001","journal-title":"Neurol Sci"},{"key":"key-10.1136\/jnnp-2013-307282-3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1468-1331.2010.03110.x","article-title":"The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis","volume":"18","author":"Devonshire","year":"2011","journal-title":"Eur J Neurol"},{"key":"key-10.1136\/jnnp-2013-307282-4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2013-307282-5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2013-307282-6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2013-307282-7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","article-title":"Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis","volume":"367","author":"Gold","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2013-307282-8","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2013-307282-9","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1021\/jm100181s","article-title":"2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists","volume":"53","author":"Bolli","year":"2010","journal-title":"J Med Chem"},{"key":"key-10.1136\/jnnp-2013-307282-10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.110.176487","article-title":"The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation","volume":"337","author":"Piali","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"(Suppl 4)","key":"key-10.1136\/jnnp-2013-307282-11","first-page":"422","article-title":"Ponesimod is a potent S1P1 receptor modulator causing efficient receptor internalisation, degradation and functional antagonism (P926)","volume":"18","author":"Gatfield","year":"2012","journal-title":"Multiple Sclerosis Journal"},{"key":"key-10.1136\/jnnp-2013-307282-12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bcp.12129","article-title":"Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study","volume":"76","author":"Brossard","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"(Suppl 1)","key":"key-10.1136\/jnnp-2013-307282-13","first-page":"S93","article-title":"Ascending multiple-dose study with ponesimod, a selective S1P1 receptor agonist: tolerability, safety, pharmacokinetics, and pharmacodynamics (P110)","volume":"91","author":"Brossard","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.1136\/jnnp-2013-307282-14","first-page":"219","article-title":"Mass balance, pharmacokinetics, and metabolism of the selective oral S1P1 receptor modulator ponesimod in humans","volume":"1","author":"Reyes","year":"2012","journal-title":"Clin Pharmacol Drug Dev"},{"key":"key-10.1136\/jnnp-2013-307282-15","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis:2005 revisions to the \u201cMcDonald Criteria\u201d","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"key-10.1136\/jnnp-2013-307282-16","doi-asserted-by":"crossref","unstructured":"WMA. World Medical Association Declaration of Helsinki\u2014Ethical Principles for Medical Research Involving Human Subjects, 2008.","DOI":"10.1515\/9783110208856.233"},{"key":"key-10.1136\/jnnp-2013-307282-17","unstructured":"ICH. Guideline for Good Clinical Practice, 1996."},{"key":"key-10.1136\/jnnp-2013-307282-18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa052643","article-title":"Oral fingolimod (FTY720) for relapsing multiple sclerosis","volume":"355","author":"Kappos","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2013-307282-19","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/S0140-6736(08)61619-0","article-title":"Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study","volume":"372","author":"Kappos","year":"2008","journal-title":"Lancet"},{"key":"key-10.1136\/jnnp-2013-307282-20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nimg.2002.1040","article-title":"Accurate, robust, and automated longitudinal and cross-sectional brain change analysis","volume":"17","author":"Smith","year":"2002","journal-title":"Neuroimage"},{"key":"key-10.1136\/jnnp-2013-307282-21","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1541-0420.2005.00344.x","article-title":"Combining multiple comparisons and modeling techniques in dose-response studies","volume":"61","author":"Bretz","year":"2005","journal-title":"Biometrics"},{"key":"key-10.1136\/jnnp-2013-307282-22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","article-title":"Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised,phase 2 study","volume":"12","author":"Selmaj","year":"2013","journal-title":"Lancet Neurol"},{"key":"key-10.1136\/jnnp-2013-307282-23","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1212\/01.wnl.0000203121.04509.31","article-title":"A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses","volume":"66","author":"O'Connor","year":"2006","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2013-307282-24","unstructured":"Novartis Pharmaceuticals Corporation. Prescribing information: GILENYA (fingolimod) capsules. http:\/\/www.pharma.us.novartis.com\/cs\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gilenya.pdf (accessed 28 Jun 2013)."},{"key":"key-10.1136\/jnnp-2013-307282-25","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/0091270004264165","article-title":"Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects","volume":"44","author":"Kovarik","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"key-10.1136\/jnnp-2013-307282-26","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1074\/jbc.C200176200","article-title":"The immune modulator FTY720 targets sphingosine 1-phosphate receptors","volume":"277","author":"Brinkmann","year":"2002","journal-title":"J Biol Chem"},{"key":"key-10.1136\/jnnp-2013-307282-27","doi-asserted-by":"crossref","first-page":"e52985","DOI":"10.1371\/journal.pone.0052985","article-title":"The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P1) and hypertension (S1P3) in rat","volume":"7","author":"Fryer","year":"2012","journal-title":"PLoS ONE"},{"key":"key-10.1136\/jnnp-2013-307282-28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cvr\/cvp086","article-title":"Sphingosine-1-phosphate receptor signalling in the heart","volume":"82","author":"Means","year":"2009","journal-title":"Cardiovasc Res"},{"key":"key-10.1136\/jnnp-2013-307282-29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2353\/ajpath.2007.060485","article-title":"Immunomodulator FTY720 induces myofibroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling","volume":"170","author":"Keller","year":"2007","journal-title":"Am J Pathol"},{"key":"key-10.1136\/jnnp-2013-307282-30","doi-asserted-by":"crossref","first-page":"14839","DOI":"10.1074\/jbc.M112.426726","article-title":"Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling","volume":"288","author":"Sobel","year":"2013","journal-title":"J Biol Chem"},{"key":"key-10.1136\/jnnp-2013-307282-31","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.2353\/ajpath.2010.091234","article-title":"Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices","volume":"176","author":"Miron","year":"2010","journal-title":"Am J Pathol"}],"updated-by":[{"DOI":"10.1136\/jnnp-2013-307282corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000}}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2013-307282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:55:37Z","timestamp":1601042137000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2013-307282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,21]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,10,17]]},"published-print":{"date-parts":[[2014,11,1]]}},"URL":"https:\/\/doi.org\/10.1136\/jnnp-2013-307282","relation":{},"ISSN":["0022-3050"],"issn-type":[{"value":"0022-3050","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3,21]]}}}